Coronavirus 2019. COVID-19, virus identified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Willingness to participate in the study Acceptable visual, auditory and alertness to participate in study Ability to understand and speak Persian Having online communication facilities such as internet and one of the smart devices such as laptop, tablet or smartphone. Ability to use online technology or caregiver to access it during quarantine. Patients who have been diagnosed with covid 19 and have a lung lesion based on the results of a CXR or CT scan with the approval of an infectious disease specialist Discharge after treatment Observance of social isolation Having a cardiac echo at the time of admission that indicates heart health
Exclusion criteria
Exclusion criteria: Having deformity in the chest mental disorder Any severe illness that impairs the movement of patients such as severe heart disease, severe musculoskeletal pain, vascular aneurysms, severe neurological diseases Pregnancy vestibular disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary function. Timepoint: At the beginning of the study (before the intervention) and at the end of the second week and at the end of the fourth week after the intervention. Method of measurement: By examining the six-minute walk test and measuring the maximum inspiratory pressure (MIP) and the percentage of blood oxygen saturation (SPO2).;Quality of life score in SF-36 questionnaire. Timepoint: At the beginning of the study (before the intervention) and at the end of the second week and at the end of the fourth week after the intervention. Method of measurement: SF-36 questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Six-minute walking test (6mwt). Timepoint: At the beginning of the study (before the intervention) and at the end of the second week and at the end of the fourth week after the intervention. Method of measurement: The patient walks a 30-meter flat path in six minutes and the distance is measured.;Maximum inspiratory pressure (MIP). Timepoint: At the beginning of the study (before the intervention) and at the end of the second week and at the end of the fourth week after the intervention. Method of measurement: En IMT K1 POWER BREATH device.;Peripheral capillary oxygen saturation. Timepoint: At the beginning of the study (before the intervention) and at the end of the second week and at the end of the fourth week after the intervention. Method of measurement: Pulse Oximeter.;Fatigue and dyspnea score. Timepoint: At the beginning of the study (before the intervention) and at the end of the second week and at the end of the fourth week after the intervention. Method of measurement: Borg scale 6-20. | — |
Countries
Iran (Islamic Republic of)
Contacts
Mashhad University of Medical Sciences